Design Therapeutics (DSGN) Operating Expenses (2020 - 2026)

Design Therapeutics has disclosed Operating Expenses across 7 years of filings, most recently posting $19.7 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $19.7 million, down 3.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.8 million (up 15.14% YoY), and the FY2025 annual result was $79.5 million, up 27.39% from the prior year.
• Operating Expenses came in at $19.7 million for Q1 2026 at Design Therapeutics, up from $18.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $22.6 million in Q2 2023 to a low of $13.4 million in Q1 2022.
• The 5-year median for Operating Expenses is $18.8 million (2023), against an average of $18.1 million.
• Across the five-year window, Operating Expenses soared 135.39% in 2022 and plunged 33.49% in 2024, its largest moves.
• Design Therapeutics' Operating Expenses stood at $19.4 million in 2022, then slipped by 22.02% to $15.1 million in 2023, then increased by 10.4% to $16.7 million in 2024, then advanced by 8.84% to $18.2 million in 2025, then advanced by 8.46% to $19.7 million in 2026.
• The last three Operating Expenses figures came in at $19.7 million (Q1 2026), $18.2 million (Q4 2025), and $19.3 million (Q3 2025), per Business Quant data.